As at May 2, 2024, the CORT stock has a price-to-earnings ratio of 21.79. This is based on the current EPS of $1.15 and the stock price of $25.06 per share. A decrease of 21% has been recorded in the PE ratio compared to the average of 27.4 of the past four quarters.
The mean historical PE ratio of Corcept Therapeutics over the last eight years is 49.0. The current 21.79 price-to-earnings ratio is 56% less than the historical average. In the past eight years, CORT's PE ratio reached its highest point in the Jun 2016 quarter at 546, with a price of $5.46 and an EPS of $0.01. The Sep 2018 quarter saw the lowest point at 10.54, with a price of $14.02 and an EPS of $1.33.
Maximum annual increase: 92.62% in 2020
Maximum annual decrease: -84.73% in 2017
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 31.84 | 48.92% |
| 2022 | 21.38 | 4.75% |
| 2021 | 20.41 | -28.21% |
| 2020 | 28.43 | 92.62% |
| 2019 | 14.76 | -28.18% |
| 2018 | 20.55 | 29.73% |
| 2017 | 15.84 | -84.73% |
| 2016 | 103.71 | N/A |
| 2015 | N/A | N/A |
| 2014 | N/A | N/A |
The current PE ratio of CORT is lower than the 3, 5 and 10-year averages.
When compared to its peers LLY and MRK, CORT's PE ratio is lower, but it is higher than JNJ's and NVS's. Corcept Therapeutics's PE ratio is trading below the peer group average of 43.18.
| Stock name | PE ratio | Market cap |
|---|---|---|
| JNJ Johnson & Johnson | 9.73 | $357.52B |
| NVS Novartis AG | 13.15 | $198.88B |
| CORT Corcept Therapeutics Inc | 20.69 | $2.48B |
| PFE Pfizer Inc | 72.64 | $155.88B |
| BMRN Biomarin Pharmaceutical Inc | 76.03 | $15.74B |
| LLY ELI LILLY & Co | 107.77 | $698.56B |
| MRK Merck & Co Inc | 912.79 | $323.65B |
| BMY Bristol Myers Squibb Co | N/A | $88.98B |
| ESPR Esperion Therapeutics Inc | N/A | $399.71M |
| MNKD Mannkind Corp | N/A | $1.19B |
The price to earnings ratio for CORT stock is 21.79 as of May 2, 2024.
Over the last 3 years, the average PE ratio for CORT stock is 24.48.
Over the last 5 years, the average PE ratio for CORT stock is 22.39.
In the last eight years, the Jun 2016 quarter recorded the highest quarterly PE ratio at 546.
CORT's current price to earnings ratio is 56% below its 8-year historical average.
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months earnings per share(EPS). As of today (May 2, 2024), Corcept Therapeutics's stock price is $25.06. The earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $1.15. Therefore, Corcept Therapeutics's price to earnings ratio for today is 21.79. PE RATIO(21.79) = STOCK PRICE($25.06) / TTM EPS($1.15)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.